Ontology highlight
ABSTRACT: Purpose
The aim of this study was to investigate the prognostic impact of two systemic inflammatory markers, the neutrophil-to-lymphocyte ratio (NLR) and the monocyte-to-lymphocyte ratio (MLR), and their possible predictive role regarding the efficacy of adjuvant trastuzumab, in 209 early breast cancer cases, 107 of which were HER2-positive.Methods
Baseline NLR and MLR values were divided into two groups, high and low, according to cut-off-points determined from the ROC curve (2.2 for NLR and 0.22 for MLR). Cox's model was utilized for survival analyses.Results
High NLR and MLR correlated with poor overall survival (OS) and breast cancer specific survival (BCSS) among all the patients (p???0.030). Among the HER2+ patients whose adjuvant treatment did not include trastuzumab (n?=?64), the survival rates were remarkably lower in patients with a high NLR as compared to those with low; 31% vs. 71% for OS and 42% vs. 74% for BCSS (p???0.014). Similarly, high MLR correlated with poor survival among these patients (p???0.020). On the contrary, among the patients who had received adjuvant trastuzumab (n?=?43), NLR or MLR did not correlate with survival. Furthermore, trastuzumab was beneficial for the HER2+ patients with high NLR/MLR, while the survival of the HER2+ patients with low NLR/MLR was good irrespective if they received adjuvant trastuzumab.Conclusions
Our results suggest that trastuzumab modulates the systemic inflammatory conditions and overcomes the poor prognostic impact of high NLR/MLR. This finding may also provide a rationale for combining trastuzumab with immuno-oncological treatments in HER2+ breast cancer.
SUBMITTER: Tiainen S
PROVIDER: S-EPMC7500503 | biostudies-literature | 2021 Jan
REPOSITORIES: biostudies-literature
Tiainen Satu S Rilla Kirsi K Hämäläinen Kirsi K Oikari Sanna S Auvinen Päivi P
Breast cancer research and treatment 20200918 1
<h4>Purpose</h4>The aim of this study was to investigate the prognostic impact of two systemic inflammatory markers, the neutrophil-to-lymphocyte ratio (NLR) and the monocyte-to-lymphocyte ratio (MLR), and their possible predictive role regarding the efficacy of adjuvant trastuzumab, in 209 early breast cancer cases, 107 of which were HER2-positive.<h4>Methods</h4>Baseline NLR and MLR values were divided into two groups, high and low, according to cut-off-points determined from the ROC curve (2. ...[more]